| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target fro...
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $4...
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $4...
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $34 price target.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the re-filing of its Abbr...
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $34 price target.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, announced that it was notified yesterday b...